Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ...

The market expects Axonics Modulation Technologies (AXNX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This ...

Axonics Modulation Technologies press release (NASDAQ:AXNX): Q1 GAAP EPS of -$0.19. Revenue of $70.7M (+46.0% Y/Y). Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period. Operating ...

As you might know, Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) just kicked off its latest first-quarter results with some very strong numbers. Sales crushed expectations at US$26m, beating ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, ...

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $2.67 per share a year ago.